We plan to prospectively explore the impact of ICI therapy-induced T-cell immunomodulation on pulmonary vascular injury and right ventricular function.
|Effective start/end date||10/1/21 → 9/30/22|
- Actelion Pharmaceuticals US, Inc. (Agmt 3/23/2022)
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.